Check out my Seeking Alpha article, I welcome a logical discussion based on facts, please back them up with links.
stevejo, you are a fool, the more you try to sound smart, the more you expose yourself to be a short idiot. talk is cheap, if you have any backbone, you will short this for all you are worth.
Hack, you are missing the point that you excluded the fact that Israel sales belong 100% to PLX. An intentional omission? Me thinks so. Additionally, the unique plant cell platform has no value whatsoever? Hmmm...it was just validated by the FDA.
Everyone is getting caught up in the sales multiple and missing the point.
The global market is tiny and is already dominated by Cerezyme and VPRIV. Both offer out of pocket patient reimbursement programs. Patients have no monetary incentive to switch to ELELYSO.
Doctors will not switch over patients to ELELYSO if current treatment is working, especially with the risk of anaphylaxis.
The market for ELELYSO is in new patients and new patients would most likely be children. The label specifies it is for adults only. Cerezyme and VPRIV labels specifically state that they are indicated for pediatric and adult patients.
I agree that the plant cell based protein expression technology that PLX developed is a great achievement but Investors need to be realistic and look at the pipeline. Nothing is past phase I. All but one of the proteins are in preclinical development. During that time each of these proteins has to pass Phase I, II and III, then NDA submission and hopefully approval. We are talking ~5 years or more for the next protein to come close to hitting the market. In my opinion PLX share price will bleed down to the low $5 range over the next weeks/months.
Your math is totally screwed up; you quoted Dr. Kedar as giving it a price to SALES (247 million) multiple of 8 and then you proceeded to do your calculation based on a price to EARNINGS (~35 million) multiple of 8. You're off by a factor of 7 so I guess your price target is really 35!